$FBIOP

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

This article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this specific stock. The content seems to be a snapshot of a financial data platform's entry for FBIOP, showing it's publicly traded and offers various analytical tools.

Original reporting
Published May 18, 2026, 5:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 18, 2026, 6:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock — source image
Decision brief

The 30-second read

$FBIOPNeutralLow
01

Why it matters

Current data suggests minimal immediate impact on trading strategies.

02

Market read

The stock has low relevance to broader market movements but may be of interest to specialized investors.

03

What to watch

Potential upcoming corporate actions or market shifts could alter the stock's relevance or impact.

Timing: low

Background

Fortress Biotech's preferred stock FBIOP is a niche financial instrument with limited trading activity.

Company-level read

Ticker impact

$FBIOPNeutralMedium confidence
Context

This is a preferred stock of Fortress Biotech with limited trading volume and low relevance to the broader market.

Expected impact

Likely negligible short-term price movement; long-term impact depends on Fortress Biotech's overall performance.

Evidence & confidence

Limited trading volume and niche status reduce the likelihood of significant price swings based solely on this information.

Market effects

Limited sector impact due to the specialized nature of preferred stocks.

Minimal regional influence; primarily relevant to existing shareholders and niche investors.

Negligible

Counterpoint

If Fortress Biotech's financial health improves significantly, FBIOP could become more attractive, warranting a reevaluation.

Key entities

  • Fortress Biotech, Inc.

    A biotechnology company listed on Nasdaq.

Related articles

$AALMed

American Airlines Management Shake-up Aims To Close Leverage With Competitors and Improve Service

American Airlines began a senior leadership reorganization, according to an Aug. 10 letter from CEO Robert Isom. Several executives are resigning or retiring, while roles expand for communications and customer service. The changes aim to improve operations and returns and close a profit gap versus Delta and United. In Q2 2026, American reported $71M net income versus $805M at United and $1.6B at Delta.

$RIOMed

Federal politics live: $2.5bn Tomago bailout 'vital' to protect Australia's largest aluminium smelter, minister says

Australia’s federal and NSW governments will announce a $2.5 billion, 10-year bailout for Tomago Aluminium, aimed at securing power supply and decarbonisation. Industry Minister Tim Ayres said the deal includes profit sharing with the Commonwealth when aluminium prices are high and $100 million for decarbonisation and demand-response. Separately, Labor will introduce a revised News Bargaining Incentive bill requiring big tech to make at least eight content deals.

$LMTMedAI 8/10

Lockheed Martin wins $211 million UAE defense contract

Lockheed Martin (NYSE:LMT) said the U.S. Missile Defense Agency awarded a $211.4 million contract modification to manufacture THAAD missile defense launchers for the United Arab Emirates. The change raises the 2019 contract total to $1.05 billion, with production from Aug 2026 to Jan 2031 under Foreign Military Sales funding.

$INTCMed

5 Things to Know Before the Stock Market Opens on Tuesday

Stock futures edged higher after Monday’s decline as investors awaited AI-related earnings. Oil prices wavered after hopes for an Iran deal faded. Intel (INTC) raised its stock offering to $20B, pricing about 210.53M shares at $95. Riot Platforms (RIOT) jumped after results and a $9.1B, 20-year Anthropic compute deal. Several AI-linked earnings were scheduled.

$STEMMed

Stem, Inc.: Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary

Stem, Inc. (NYSE: STEM) said Solarmarkt Group, with EPC partner Pannonwatt, selected Stem’s PowerTrack Energy Management System to hybridize two operating utility-scale solar plants in Hungary. The five-year agreement covers adding 40 MW/80 MWh batteries to each site, targeting commercial operation by Sept 2026 and participation in Hungary’s aFRR market.